Drug Inhibits Acute Leukemia Cell Growth
Author: University of Texas M. D. Anderson Cancer Center
Researchers find drug that inhibits acute leukemia cell growth - Pre-clinical study shows 50 percent reduced tumor cell burden.
Main DigestResearchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have discovered how to turn off a certain receptor that promotes the growth of leukemia cells.
Researchers find drug that inhibits acute leukemia cell growth - Pre-clinical study shows 50 percent reduced tumor cell burden
Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have discovered how to turn off a certain receptor that promotes the growth of leukemia cells. The pre-clinical study was presented today in a platform session at the 22nd annual meeting of the American Society of Pediatric Hematology/Oncology (ASPHO).
"There is a certain receptor we now know is expressed in acute myeloid leukemia (AML) cells called Tropomyosin Receptor Kinase A (TRKA)," said Mauricio Ghisoli, M.D., fellow at the Children's Cancer Hospital at M. D. Anderson. "When TRKA gets turned on by a nerve growth factor (NGF) ligand, the AML cells start to rapidly grow."
Ghisoli and researchers at M. D. Anderson have found that using a TRK inhibitor, AZ23, turns off NGF, which led to a 50 percent reduction of AML cells in mice with no immune system. When studied in mice with an immune system present, researchers found that 60 percent of the mice treated with AZ23 had long-term survival with no presence of leukemia cells.
They also found AZ23 to be more effective in human AML cell lines that expressed higher levels of TRKA. This pre-clinical discovery could potentially allow clinicians to decipher which patients may have the best response to the drug in the future, explained Ghisoli.
Acute leukemia is the most common cancer in children, according to the American Cancer Society. Acute lymphoblastic leukemia, the more common type, has a cure rate of 80 percent, but children with the rarer type, AML, have only a 50 percent chance of a cure in comparison.
"Young patients with acute lymphocytic leukemia have a great chance of being cured using the standard treatments available out there today," said Patrick Zweidler-McKay, M.D., Ph.D., assistant professor at the Children's Cancer Hospital and senior investigator. "However, we have to find alternatives to increase the chance of cure for pediatric patients diagnosed with AML. Understanding how to turn off switches that promote cancer cell production is one way to do this."
In pre-clinical tests on solid tumor cell lines, AZ23 was found effective against the tumors. A Phase I clinical trial is planned to open this year for adults with solid tumor cancers.
Other investigators on the study were Wendy Fang, M.D., Alejandro Levy, M.D., Timothy Graham, Riitta Nolo, Ph.D., and Sankaranarayanan Kannan, Ph.D., from the Children's Cancer Hospital, and Christine Pien, Ph.D., and Jeffrey Brown, Ph.D. from AstraZeneca Pharmaceuticals.
About M. D. Anderson
The University of Texas M. D. Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. M. D. Anderson is one of only 41 Comprehensive Cancer Centers designated by the National Cancer Institute. For four of the past six years, M. D. Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News and World Report.
About the Children's Cancer Hospital at M. D. Anderson
The Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center has been serving children, adolescents and young adults for more than 50 years. In addition to the groundbreaking research and quality of treatment available to pediatric patients, the Children's Cancer Hospital provides its patients with comprehensive programs that help the children lead more normal lives during and after treatment. For further information, visit the Children's Cancer Hospital Web site at www.mdanderson.org/children.
- 1 - Osgood-Schlatters Disease: Causes, Diagnosis and Treatments : Disabled World (2009/03/20)
- 2 - Screening Lowers Severe Jaundice Risk in Babies : University of California San Francisco (2009/09/28)
- 3 - Jaundice in the Newborn Baby : Cecilia Koh (2017/10/03)
- 4 - Coaxing Kids Through Vaccinations - Pain Expectation is Pain Reality for Children : University of California - Riverside (2018/06/04)
- 5 - Fetal Alcohol Spectrum Disorder in Children : JoAnn Collins (2009/03/23)
- 6 - Types of Genetic Mutations Associated with Nephrotic Syndrome Identified : Fundação de Amparo à Pesquisa do Estado de São Paulo (2018/03/24)
- 7 - SIDS: Sudden Infant Death Syndrome Information : Disabled World (2009/02/19)
• Disabled World is strictly a news and information website provided for general informational purpose only and does not constitute medical advice. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World.
• Please report outdated or inaccurate information to us.